When business updates start to come in or when some FMCG or auto companies indicate that things are not all good in the rural space, we may...

As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Small-cap investing is not just about finding stocks that can rise faster than the market, which is the assumption with which most investor...

Sun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...

Strides Pharma Science is preparing to enhance its presence in Sub-Saharan Africa by acquiring branded generic products from Sandoz AG, wit...

"As we achieve formidable positions in many markets, our strategy now entails enhancing focus on select countries from our geographical pre...

Ranbaxy Laboratories has launched its cholesterol lowering drug atorvastatin, the generic version of the world’s best selling drug Lipitor ...

Lupin has acquired 60% stake in Pharma Dynamics, a South African generic marketing firm.